KPTI Karyopharm Therapeutics Inc. · XNAS
1.48 -8.6% as of Sep 11, 14:55 ET
fans
What's happening Live detector signal Generated 19:58 ET
Share structure
Free float
18.0M
2026-02-19
Shares out
22.7M
latest detail
Market cap
$36.7M
at ref price
Short interest
54.6%
2026-08-31
Float rotation
0.31×
latest snapshot
20d dollar vol
$2.0M
baseline
Supply intelligence
Gap quality
clean gap · 74
live supply-pressure model
Supply factor
negative gap pressure
detector reason
Supply factor
meaningful float rotation
detector reason
Supply factor
high short interest
detector reason
Supply factor
nano-cap supply profile
detector reason

This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.

Filings and news
2026-09-11 14:55 ETSignalKaryopharm Therapeutics Inc is down 8.6%, at 1.48, on $8.3M traded, 5.3× 20-day volume, 0.31× float rotation. Score 74. Primary driver: 31.2% float rotation. Supply intelligence: clean gap · 74.
2026-09-118-KItem 1.01 — Entry into a material definitive agreement; Item 3.02 — Unregistered sales of equity securities +1 more SEC
2026-08-318-KItem 8.01 — Other events SEC
2026-08-1310-QQuarterly report SEC
2026-08-138-KItem 2.02 — Results of operations and financial condition; Item 9.01 — Financial statements and exhibits SEC
2026-07-318-KItem 8.01 — Other events SEC
2026-07-178-KItem 5.02 — Director or officer departure/election/appointment SEC
2026-06-14 06:30 ETFDA / ClinicalMenarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress News
2025-03-01 08:45 ETAnalyst RatingInternational Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month News
2024-11-25 11:00 ETGeneralGlioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033 News
2024-09-05 14:16 ETEarnings GuidanceDown -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround News
Latest detector signalscore 74
score 74